Dystrogen Therapeutics and Bramble Bio Announce Strategic Manufacturing Partnership to Advance DT-DEC01 for Duchenne Muscular Dystrophy

Dystrogen Therapeutics, a biotechnology company dedicated to developing advanced therapies for rare neuromuscular diseases, today announced a strategic partnership with Bramble Bio to manufacture its lead candidate DT-DEC01. This highly innovative therapy leverages the ex-vivo fusion of allogeneic human myoblast cells with autologous myoblasts derived from patients with Duchenne Muscular Dystrophy (DMD).

Under the agreement, Bramble Bio will oversee the specialized manufacturing of DT-DEC01, while Dystrogen Therapeutics will progress the therapy through clinical development using the Advanced Therapy Medicinal Products – Hospital Exemption (ATMP-HE) pathway in Europe, enabling access for DMD patients who urgently need novel treatment options.

Duchenne Muscular Dystrophy is a devastating genetic disorder affecting approximately one in every 3,500–5,000 live male births worldwide, characterized by progressive muscle degeneration and weakness. DT-DEC01 represents a promising step forward, aiming to restore and preserve muscle function through a unique myoblast fusion-based approach.

Kris Siemionow, CEO of Dystrogen Therapeutics, commented:

“This partnership with Bramble Bio marks a pivotal milestone in our mission to bring transformative therapies to patients living with Duchenne Muscular Dystrophy. By combining our innovative therapeutic approach with Bramble Bio’s deep expertise in advanced therapy manufacturing, we are well-positioned to accelerate development and provide new hope to patients and their families.”

Simon Boa, Managing Director of Bramble Bio, added:

“We are proud to collaborate with Dystrogen Therapeutics on such a groundbreaking program. Manufacturing advanced cell-based therapies like DT-DEC01 requires precision, reliability, and innovation. Our team is committed to ensuring that this therapy can be delivered safely and effectively to patients who urgently need better treatment options.”

This partnership underscores the commitment of both companies to advancing cell and gene therapy platforms and delivering meaningful innovation in the treatment of rare genetic diseases.
________________________________________
About Bramble Bio
Bramble Bio is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to advancing the cell and gene therapy industry. The company provides end-to-end support, including process development, optimization, and cGMP-compliant manufacturing for advanced therapy medicinal products (ATMPs). With deep expertise in cell and gene therapy platforms, Bramble Bio partners with innovators worldwide to translate groundbreaking science into scalable, high-quality therapies. Its mission is to enable the successful development and delivery of transformative treatments that improve patient lives globally.

About Dystrogen Therapeutics
Dystrogen Therapeutics is a clinical stage chimeric cell company, focusing on muscle wasting disorders. Chimeric cells have shown remarkable functional outcomes: increased muscle force, reduced muscle fatigue, and greater muscle fiber diameter and volume.